Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag.

ABSTRACT:

Background & aims

Despite limitations, platelet transfusion has been used to minimise bleeding risk in patients with thrombocytopaenia. Lusutrombopag is an oral, thrombopoietin receptor agonist approved for treatment of thrombocytopaenia associated with chronic liver disease in patients undergoing planned invasive procedures. This post-hoc analysis assessed the magnitude of platelet count change based on the integrated per-protocol population from 2 similar phase III multicentre, randomised, double-blind, placebo-controlled trials.

Methods

Adults with chronic liver disease-induced thrombocytopaenia and platelet count <50 (× 10⁹/L) received lusutrombopag 3 mg or placebo ?7 days before invasive procedure scheduled 9-14 days after randomisation. Platelet transfusion was required per protocol if the platelet count remained <50 no more than 2 days before the planned invasive procedure. Post-hoc analysis included: proportion of patients with platelet count ?50, ?1.5-fold increase, and a doubling of platelet count; maximum and maximum change in platelet count; and platelet count time course.

Results

Platelet count ?50, a platelet count increase ?1.5-fold, and at least a doubling in platelet count were achieved in 88.3%, 86.9%, and 52.6% of patients in the lusutrombopag group (n = 137) vs. 58.6%, 32.3%, and 6.0% of patients in the placebo group (n = 133), respectively. In the lusutrombopag group, median maximum platelet count across baseline platelet counts of <30, ?30 to <40, and ?40 was 46, 76, and 87, respectively. Median maximum change in platelet count by baseline platelet count was +24, +42, and +40, respectively. Patients who received lusutrombopag without platelet transfusion achieved a median platelet count ?50 for 3 weeks.

Conclusions

Patients treated with lusutrombopag experienced a clinically relevant response in platelet count for a substantial duration of time.

Lay summary

Patients with low platelet counts caused by chronic liver disease may not receive planned invasive procedures or surgeries because of an increased risk of bleeding. Lusutrombopag has previously demonstrated efficacy in raising platelet counts and is approved to treat chronic liver disease patients with low platelet counts in advance of a planned surgery. Physicians need to understand more clearly what to expect in terms of platelet count change when using lusutrombopag; this integrated analysis provides data to help guide its clinical application.

SUBMITTER: Brown RS 

PROVIDER: S-EPMC7887643 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature